L H Fraiser

Learn More
Cyclophosphamide, an orally active alkylating agent, is widely used to treat a variety of malignant and nonmalignant disorders. Although it has some tumour selectivity, it also possesses a wide spectrum of toxicities. The requirement of metabolic activation before cyclophosphamide exerts either its therapeutic or toxic effects is well established, but has(More)
Acrolein is the metabolite of cyclophosphamide (CP) believed to be involved in the bladder toxicity associated with this anticancer drug. The mechanism by which this extremely reactive intermediate is delivered to the bladder is not known. Glutathione (GSH) readily conjugates with acrolein, and the acrolein mercapturate S-(3-hydroxypropyl)-N-acetylcysteine(More)
A single intraperitoneal dose (200 mg/kg) of cyclophosphamide (CP) resulted in significantly less injury to the C57/B16 strain than to the ICR strain of mice. Maximal thymidine incorporation into total lung DNA, an indirect index of lung injury, and pulmonary hydroxyproline content, a marker of fibrosis, were 56 +/- 10% and 69 +/- 9 of ICR mice,(More)
Cyclophosphamide (CP) undergoes metabolic activation, generating phosphoramide mustard and acrolein which are believed to be responsible for the cytostatic and toxic effects, respectively. In this study, CP-induced bladder toxicity (hemorrhagic cystitis) was found to be significantly greater in the ICR than the C57BL/6N (C-57) strain of mice. Strain(More)
About hazardous waste incineration Dear Editor: "Managing the Health Impacts of Waste Incineration" {Environ. Sci. Technol. 2000, 34 (17), 380A-387A), as it relates to hazardous waste (HW) incineration, contains errors and omissions. The article states that emissions can increase significantly during startup/shutdown, and there is concern that Maximum(More)
  • 1